A decade of research on the natural history of HIV infection: Part 1. Markers

Clinical and Investigative Medicine

Volumn 19, Issue 2, 1996, Pages 111-120

  Strathdee, Steffanie A ^a,b   O'Shaughnessy, Michael V ^a,b   Montaner, Julio S G ^a,b   Schechter, Martin T ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN DERIVATIVE; MARKER; NEOPTERIN; TUMOR NECROSIS FACTOR; VIRUS DNA; VIRUS RNA;

APOPTOSIS; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROVIRUS; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BIOPTERIN; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; IMMUNOGLOBULINS; NEOPTERIN; VIREMIA;

EID: 0029981839     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Munoz A, Wang MC, Bass S et al: Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Am J Epidemiol 1989; 130: 530-539
2. Fahey JL, Taylor JMG, Detels R et al: The prognostic value of cellular and serologic markers in infection with HIV-1. N Engl J Med 1990; 322: 166-172
3. Farewell VT, Coates RA, Fanning MM et al: The probability of progression to AIDS in a cohort of male sexual contacts of men with HIV disease. Int J Epidemiol 1992; 21: 131-135
4. Hendriks JMC, Medley G, Van Griensven GJP et al: The treatment-free incubation period of AIDS in a cohort of homosexual men. AIDS 1993; 7: 231-239
5. Sheppard HW, Lang W, Ascher MS et al: The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7: 1159-1166
6. Easterbrook PJ: Non-progression in HIV infection. AIDS 1994; 8: 1179-1182
7. Schulte P: Methodologic issues in the use of biologic markers in epidemiologic research. Am J Epidemiol 1987; 126: 1006-1016
8. Brookmeyer R, Gail MH, Polk BR: The prevalent cohort study and the acquired immunodeficiency virus. Am J Epidemiol 1987; 126: 14-24
9. Goedert JJ, Biggar R, Weiss SH et al: Three-year incidence of AIDS in five cohorts of HTLV-III infected risk group members. Science 1986; 231: 992-995
10. Levy JA: HIV and the pathogenesis of AIDS. JAMA 1989; 261: 2997-3006
11. Phillips AN: Studies of prognostic markers in HIV infection: implications for pathogenesis. AIDS 1991; 6: 1391-1394
12. 2-microglobulin, immunoglobulin A, and erythrocyte sedimentation rate. AIDS 1993; 7: 813-821
13. Gottlieb MS, Schroff R, Schranker HM et al: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med 1981; 305: 1425-1431
14. Taylor JMG, Fahey JL, Detels R et al: CD4 percentage, CD4 number and CD4:CD8 ratio in HIV infection: which to choose and how to choose. J Acquir Immun Defic Syndr 1989; 2: 114-124
15. Coates RA, Farewell VT, Raboud J et al: Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. J Clin Epidemiol 1992; 45: 245-253
16. Raboud JM, Haley L, Montaner JSG et al: Sources of variation in CD4 lymphocyte counts. J Acquir Immun Defic Syndr Hum Retroviruses 1995; 10: 67-73
17. Burcham J, Marmor M, Dubin N et al: CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 1991; 5: 365-372
18. Friedman-Kien AE, Laubenstein LJ, Rubenstein P et al: Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 1982; 96: 700-704
19. Eyster ME, Gai MH, Ballard JO et al: Natural history of HIV infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med 1987; 107: 1-6
20. Fernandez-Cruz E, Desco M, Montes MG et al: Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected intravenous drug users. AIDS 1990; 4: 987-994
21. Alcabes P, Selwyn PA, Davenny K et al: Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994; 8: 107-115
22. Sande MA, Carpenter CCJ, Cobbs CG et al: Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1993; 270: 2583-2589
23. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992; 41 (RR-4)
24. Therapeutic Guidelines for the Treatment of HIV/AIDS, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, 1993
25. Fischl MA: State of antiretroviral therapy with zidovudine. AIDS 1989; 3: 137-143
26. Lundgren JD, Barton SE, Lazzarin A et al: Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. Clin Infect Dis 1995; 21: 106-113
27. Chin DP, Hopewell PC, Yajko DM et al: Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169: 289-295
28. Murray HW, Godbold JH, Jurica KB et al: Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: reappraisal of risk and predictive factors. Am J Med 1989; 86: 533-538
29. Lefrere J-J, Courouce A-M, Lucotte G et al: Follow-up of subjects with isolated and persistent anti-core antibodies to HIV. AIDS 1988; 2: 287-290
30. Phair J, Munoz A, Detels R et al: The risk of Pneumocystic carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 161-165
31. 6/L of AIDS-defining clinical disease. AIDS 1994; 8: 1577-1583
32. Unexplained CD4+ T-lymphocyte depletion in persons without evident HIV infection United States. MMWR 1992; 41: 541-545
33. Fauci AS: CD4+ T-lymphocytopenia without HIV infection no lights, no camera, just facts. N Engl J Med 1993; 328: 429-430
34. Veugelers PJ, Schechter M, Tindall B et al: Differences in time from HIV seroconversion to CD4+ lymphocyte end-points and AIDS in cohorts of homosexual men. AIDS 1993; 7: 1325-1329
35. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clin Infect Dis 1993; 17: 802-810
36. Revision of the surveillance case definition for AIDS in Canada. Can Med Assoc J 1994; 150: 531-532
37. World Health Organization: WHO case definitions for AIDS surveillance in adults and adolescents. WHO Wkly Epidemiol Rep 1994; 69: 273-275
38. Chevret S, Roquin H, Ganne P et al: Prognostic value of an elevated CD8 lymphocyte count in HIV infection: results of a prospective study of 152 asymptomatic HIV-positive individuals. AIDS 1992; 6: 1349-1352
39. Molina JM, Ferchal F, Chevret S et al: Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. AIDS 1994; 8: 27-33
40. Mackewicz C, Levy JA: CD8+ cell anti-HIV activity: non-lytic suppression of virus replication. AIDS Res Hum Retroviruses 1992; 8: 1039-1050
41. Gomez AM, Easterbrook MD, Smaill FM et al: Susceptibility of syncytia-inducing variants of HIV-1 to inhibition by CD8+ T lymphocytes. Can J Infect Dis 1995; 6 (suppl B): 13B
42. Koot M, Keet IPM, Aster HVV et al: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1994; 118: 681-688
43. Buchbinder SP, Katz MH, Hessol NA et al: Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8: 1123-1128
44. Schrager LK, Young JM, Fowler MG et al: Long-term survivors of HIV-1 infection: definitions and research challenges. AIDS 1994; 8: S95-S108
45. Walker B, Plata F: Cytotoxic T lymphocytes against HIV. AIDS 1990; 4: 177-184
46. Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991; 87: 1462-1466
47. Carmichael A, Jin X, Sissons P et al: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177: 249-256
48. Riviere Y, McChesney M, Porrot F et al:: Role of HIV specific cytotoxic effector cells in disease progression. [abstract WS-B03-4] 9th International Conference on AIDS, Berlin, June 6-11, 1993
49. Buchbinder SP, Elbeik T, Harrer T et al: Healthy long-term HIV positives: viral burden and cell-mediated immunity. [abstract 007C] 10th International Conference on AIDS, Yokohama, Japan, Aug 7-12, 1994
50. Knight B, Salvato P, Thomson C: Laboratory markers of long-term survivors with HIV disease. J Acquir Immune Defic Syndr Hum Retroviruses 1994; 7: S21-S27
51. Rinaldo C, Huang X-L, Fan Z et al: Low viral load and high anti-HIV-1 cytotoxic T lymphocyte memory responses correlate with lack of HIV-1 disease in long-term nonprogressors. [abstract 170] 2nd National Conference on Human Retroviruses and Related Infections, Washington, Jan 29-Feb 2, 1995
52. H2 hypothesis of HIV infection: new insights. Immunol Today 1993; 15: 575-581
53. Legac E, Autran B, Merle-Beral H et al: CD4+ CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood 1992; 7: 1746-1753
54. Fuchs D, Hansen A, Reibnegger G et al: Neopterin as a marker for cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150-155
55. Rogstad KE, Morgan L, Hughes J et al: Urinary neopterin as a prognostic index of survival time in HIV-1 infection. [abstract PB0044] 10th International Conference on AIDS, Yokohama, Japan, Aug 7-12, 1994
56. Sheppard HW, Ascher MS, McRae B et al: The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr 1991; 4: 704-712
57. 2-microglobulin in HIV-1-seronegative injecting drug users. AIDS 1993; 7: 361-367
58. Munoz A, Vlahov D, Solomon L et al: Prognostic indicators for development of AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1992; 5: 694-700
59. Black C, Farzadegan H, Henrard D et al: Serologic and viral correlates of HIV-1 disease progression: a multicenter AIDS cohort report. [abstract PB0102] 10th International Conference on AIDS, Yokohama, Japan, Aug 7-12, 1994
60. 2-microglobulin, and neopterin serum levels in patients with Kaposi's sarcoma and AIDS. J Acquir Immune Defic Syndr 1991; 4: 871-880
61. Moss AR, Bacchetti P, Osmond D et al: Seropositivity for HIV and the development of AIDS or ARC: three year follow-up of the San Francisco General Hospital cohort. BMJ 1988; 296: 745-750
62. 2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci USA 1974; 71: 2123-2127
63. 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis 1989; 159: 1029-1036
64. Osmond DH, Shiboski S, Bacchetti P et al: Immune activation markers and AIDS prognosis. AIDS 1991; 5: 505-511
65. Zangerle R, Fuchs D, Reibnegger G et al: Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 1991; 5: 985-991
66. 2-microglobulin levels in drug users: the influence of risk behaviour. AIDS 1991; 5: 1021-1024
67. Multicohort Analysis Project Workshop, Part I. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. AIDS 1994; 8: 911-921
68. Kramer A, Biggar RJ, Hampl H et al: Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness specific. Am J Epidemiol 1992; 136: 71-80
69. Chang Y, Cesarman E, Pessin MS et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869
70. Huang YQ, Li JJ, Kaplan MH et al: Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995; 345: 759-760
71. Biggar RJ, Melbye M, Ebbesen P et al: Variation in HTLV-III antibodies in homosexual men: decline before onset of illness related to AIDS. BMJ 1985; 291: 997-998
72. Lange JAM, Paul D, Huisman HG et al: Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. BMJ 1986; 293: 1459-1462
73. Allain J-P, Laurian Y, Paul D et al: Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. N Engl J Med 1987; 317: 1121-1124
74. Fenouillet E, Blanes N, Coutellier A et al: Monitoring of antibodies against HIV-1 p25 core protein as prognostic marker. J Infect Dis 1993; 166: 611-616
75. Keet IPM, Krunen P, Koot M et al: Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7: 51-57
76. Strathdee SA, Frank J, Leblanc M et al: Quantitative measures of HIV-specific antibodies predict progression to AIDS. J Infect Dis 1995; 172: 1375-1379
77. World Health Organization: Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. WHO Wkly Epidemiol Rep 1990; 37: 281-283
78. Schechter MT, Craib KJP, Le TN et al: Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 1989; 3: 347-353
79. Gafa S, Giudici MG, Pezzotti P et al: IgA as a marker of clinical progression among HIV-seropositive intravenous drug users. J Infect 1993; 26: 33-38
80. Craib KJP, Schechter MT, Le TN et al: Imputed and crude estimates of lead time infection in a seroprevalent cohort of homosexual men. [abstract] 6th International Conference on AIDS, San Francisco, June 20-24, 1990
81. Creemers PC, O'Shaughnessy MV, Boyko WJ: Increased interleukin-2 receptor expression after mitogen stimulation on CD4- and CD8-positive lymphocytes and decreased interleukin-2 production in HTLV-III antibody-positive symptomatic individuals. Immunology 1986; 59: 627-629
82. Tateno Y, Takahashi T, Tateno M et al: Soluble IL-2 receptor (sIL-2R) in seropositive individuals. [abstract PB0044] 10th International Conference on AIDS, Yokohama, Japan, Aug 7-12, 1994
83. Clerici M, Stocks NI, Zajac RA et al: Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339: 383-385
84. Simmonds P, Beatson D, Cuthbert RJ et al: Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 1991; 338: 1159-1163
85. Boue F, Wallon C, Goujard C et al: HIV induces IL-6 production by human B lymphocytes. J Immunol 1992; 148: 3761-3767
86. H0 cells. Science 1994; 265: 244-248
87. H2 predominance in HIV-infected individuals. Science 1994; 265: 248-252
88. Voth R, Rossol S, Graff E et al: Natural killer cell activity as a prognostic parameter in the progression to AIDS. J Infect Dis 1988; 157: 851-852
89. Lifson AR, Buchbinder SP, Sheppard HW et al: Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis 1991; 163: 959-965
90. H2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-111
91. Fan J, Bass HZ, Fahey JL: Elevated IFN- and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993; 151: 5031-5040
92. Rook AH, Lane HC, Folks T et al: Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV infected T-cells. J Immunol 1987; 138: 1064-1067
93. Meyaard L, Otto SA, Keet IPM et al: Programmed death of T cells in human immunodeficiency virus infection. J Clin Invest 1994; 93: 982-988
94. Pedersen C, Nielsen C, Vestergaard BF et al: Temporal relation of antigenemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. BMJ 1987; 295: 567-568
95. Paul DA, Falk LA, Kessler HA: Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol 1987; 22: 357-363
96. Goudsmit J, Dewolf F, Paul DA et al: Expression of HIV antigen in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986; 2: 177-180
97. Polk BF, Fox R, Brookmeyer R et al: Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987; 316: 61-66
98. McHugh TM, Stites DP, Busch MP et al: Relation of circulating levels of HIV antigen, antibody to p24, and HIV-containing immune complexes in HIV infected patients. J Infect Dis 1988; 158: 1088-1091
99. Bollinger RC Jr, Kline RL, Francis HL et al: Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. J Infect Dis 1992; 165: 913-916
100. O'Shaughnessy MV, Cassol SA: Laboratory diagnosis of HIV infection. Can J Infect Dis 1994; 5 (suppl E): 7E-12
101. Coombs R, Collier AC, Allain J-P et al: Plasma viremia in HIV infection. N Engl J Med 1989; 321: 1626-1631
102. Ho DD, Mougdil T, Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321: 1621-1625
103. Daar ES, Mougdil T, Meyer RD et al: Transient high levels of viremia in patients with primary HIV-1 type infection. N Engl J Med 1991; 324: 961-964
104. Katzenstein DA, Holodniy M, Israelski DM et al: Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr 1992; 5: 107-112
105. Ou CY, Kwok S, Mitchell SW et al: DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988; 239: 295-297
106. Wei X, Ghosh SK, Taylor ME et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122
107. Ho DD, Neumann AU, Perelson AS et al: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126
108. Schechter MT, Neumann PW, Weaver MS et al: Low HIV-1 proviral DNA burden detected by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression. AIDS 1991; 5: 373-379
109. Verhofstede C, Reniers S, Van Wanzeele F et al: Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS 1994; 8: 1421-1427
110. Wattel E, Mariotti M, Agis F et al: Quantification of HTLV-1 proviral copy number in peripheral blood of symptomless carriers from the French West Indies. J Acquir Immune Defic Syndr 1992; 5: 943-946
111. Bieniasz PD, Ariyoshi K, Bourelly MAD et al: Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals. AIDS 1992; 7: 803-806
112. Yerly S, Chamot E, Hirschel B et al: Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters. J Infect Dis 1992; 166: 269-276
113. Merzouki A, Mo T, Vellani M et al: Accurate and differential quantitation of HIV-1 tat, rev and nef mRNAs by competitive PCR. J Virol Methodol 1994; 50: 115-128
114. Michael NL, Mo T, Merzouki A et al: Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 1995; 69: 1868-1871
115. Feinberg MB, Jarrett RF, Aldovini A et al: HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 1986; 46: 807-817
116. Greenspan D, Greenspan JS, Hearst NG et al: Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis 1987; 155: 475-481
117. Lifson AR, Hilton JF, Westenhouse JL et al: Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts. AIDS 1994; 8: 73-79
118. Melbye M, Grossman RJ, Goedert JJ et al: Risk of AIDS after herpes zoster. Lancet 1987; 1: 728-730
119. Kaslow RA, Ostrow DG, Detel R et al: The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126: 310-318
120. Klein R, Harris CA, Small CA et al: Oral candidiasis in high risk patients as the initial manifestation of AIDS. N Engl J Med 1984; 311: 354-358
121. Katz MH, Greenspan D, Westenhouse J et al: Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992; 6: 95-100
122. Osmond D, Chaisson RE, Moss AR et al: Lymphadenopathy in asymptomatic patients seropositive for HIV. N Engl J Med 1987; 317: 246
123. Cooper DA, Gold J, MacLean P et al: Acute AIDS retrovirus infection - definition of a clinical illness associated with seroconversion. Lancet 1985; 1: 537-540
124. Tindall B, Barker S, Donovan B et al: Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988; 148: 945-949
125. 6/l, AIDS, and death from AIDS? BMJ 1994; 309: 1535-1537
126. Sinicco A, Fora R, Sciandra M et al: Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993; 6: 575-581
127. Dorrucci M, Rezza G, Vlahov D et al: Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. AIDS 1995; 9: 597-604
128. Schechter MT, Craib KJP, Le TN et al: Susceptibility to AIDS progression appears early in HIV infection. AIDS 1990; 4: 185-190